Type 2 diabetes mellitus. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: coenzyme Q10 capsule, 100 mg, twice per day, for eight weeks, edible. Health Burst brand. Intervention 2: Cellulose acetate, 100 mg, two capsules per day, for eight weeks, edible, made
Placebo
coenzyme Q10 capsule, 100 mg, twice per day, for eight weeks, edible. Health Burst brand
Cellulose acetate, 100 mg, two capsules per day, for eight weeks, edible, made in Shiraz School of Pharmacy
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Type 2 diabetic patients, with body mass index 20-30. Exclusion criteria: Patients with any chronic renal, hepatic and gastrointestinal disorders, using anticoagulants, lipid lowering medications and ß-blockers, consumption of vitamin-mineral supplements, following specific diets and smokers. In the case of decreasing or increasing the blood glucose lowering medications the patient will be excluded from the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood sugar. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: BT 1500 autoanalyzer, unit: mg/dl.;Hemoglobin A1c. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: HPLC method, will be reported as percentage.;Insulin. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: ELISA method, unit: µIU/ml.;Insulin resistance. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: according to the formula.;High-sensitivity C-reactive protein. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: ELISA method, unit: ng/ml.;Adiponectin. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: ELISA method, unit: µg/ml.;Triglyceride. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: BT-1500 autoanalyzer, unit: mg/dl.;Total cholesterol. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: BT-1500 autoanalyzer, unit: mg/dl.;LDL- cholesterol. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: BT-1500 autoanalyzer, unit: mg/dl.;HDL- cholesterol. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: BT-1500 autoanalyzer, unit: mg/dl.;Malondialdehyde. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: spectrophotometry, unit: µmol/l.;Blood pressure. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: mercury sphygmomanometer, unit: mmHg. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hip circumference. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: measuring with a tape measure, unit: centimeter.;Weight. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: analog scale, unit: kg.;Body Mass Index. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: according to the formula, unit: kg/m2.;Waist circumference. Timepoint: at the beginning of intervention, at the end of intervention. Method of measurement: measuring with a tape measure, unit: centimeter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahsa Moazen
Shiraz University of Medical Sciences
Outcome results
None listed